PMID- 34140772
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 17
DP  - 2021
TI  - Online Survey of Clinical Practice in Patients with Schizophrenia Treated with 
      Long-Acting Injectable Aripiprazole or Paliperidone Palmitate.
PG  - 1881-1892
LID - 10.2147/NDT.S303292 [doi]
AB  - BACKGROUND: To obtain real-world evidence of functional improvements during 
      atypical long-acting injectable (aLAI) therapy in recent-onset schizophrenia, an 
      online survey was conducted to assess the impact of aripiprazole once-monthly 
      injectable 400 mg (AOM 400; partial D(2) receptor agonist) and paliperidone 
      palmitate once-monthly (PP1M; injectable, full D(2) receptor antagonist). 
      METHODS: Psychiatrists provided data for their 2 most recent AOM 400 patients, 2 
      most recent PP1M patients. Survey included 2000 patient cases (1000 AOM 400; 1000 
      PP1M). Eligible patients were aged 18-35 years, had been diagnosed with 
      schizophrenia within 5 years, received AOM 400 or PP1M continuously for >/=6 months 
      according to approved labels (mean durations: 1.6 and 1.7 years with AOM 400 and 
      PP1M, respectively). Assessments included Global Assessment of Functioning (GAF) 
      Scale, Personal and Social Performance Scale, Positive and Negative Syndrome 
      Scale, and Quality of Life Scale. GAF assessments were done retrospectively and 
      also at the time of survey. RESULTS: Baseline mean GAF scores were 43.3 and 43.8 
      for AOM 400 and PP1M, respectively, indicating serious symptoms/functional 
      impairment in both groups. Mean improvements following AOM 400 and PP1M therapy 
      were 19.7 and 16.3 points, respectively (final scores in mild functional 
      impairment category). Other measures assessing symptoms/functionality/quality of 
      life demonstrated the benefits of long-term aLAI therapy. CONCLUSION: 
      Schizophrenia patients with serious functional impairment prior to current aLAI 
      treatment showed improvements in functional outcome after AOM 400 or PP1M 
      therapy. These results suggest functional improvements with aLAIs are apparent 
      not only in research but also real-world settings.
CI  - (c) 2021 Such et al.
FAU - Such, Pedro
AU  - Such P
AD  - Medical Strategy and Communication, H. Lundbeck A/S, Valby, 2500, Denmark.
FAU - Olivares, Jose Manuel
AU  - Olivares JM
AD  - Department of Psychiatry, Hospital Alvaro Cunqueiro, Health Research Institute 
      Galicia Sur (IISGS), CIBERSAM, Vigo, Spain.
FAU - Arias, Lizbeth
AU  - Arias L
AD  - Medical Strategy and Communication, H. Lundbeck A/S, Valby, 2500, Denmark.
FAU - Troels Berg, Mette
AU  - Troels Berg M
AD  - Medical Strategy and Communication, H. Lundbeck A/S, Valby, 2500, Denmark.
FAU - Madera, Jessica
AU  - Madera J
AD  - Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, 
      Inc, Princeton, New Jersey, 08540, USA.
LA  - eng
PT  - Journal Article
DEP - 20210610
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC8203189
OTO - NOTNLM
OT  - AOM
OT  - antipsychotic treatment
OT  - aripiprazole
OT  - aripiprazole once-monthly injectable
OT  - long-acting injectable
OT  - paliperidone palmitate once-monthly injectable
COIS- PS, LA, and MTB: employees of Lundbeck, JMO: paid positions, honoraria, and/or 
      advisory boards with/received from Angelini, AstraZeneca, Bristol-Myers, Casen 
      Recordati, Esteve, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Novartis, Otsuka, 
      Pfizer, Sanofi, and grants from National Institute of Health Carlos III, Galician 
      Innovation Agency, and the Spanish National Plan on Drugs, JM: employee of 
      Otsuka. The authors report no other conflicts of interest in this work.
EDAT- 2021/06/19 06:00
MHDA- 2021/06/19 06:01
PMCR- 2021/06/10
CRDT- 2021/06/18 06:40
PHST- 2021/02/02 00:00 [received]
PHST- 2021/05/24 00:00 [accepted]
PHST- 2021/06/18 06:40 [entrez]
PHST- 2021/06/19 06:00 [pubmed]
PHST- 2021/06/19 06:01 [medline]
PHST- 2021/06/10 00:00 [pmc-release]
AID - 303292 [pii]
AID - 10.2147/NDT.S303292 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2021 Jun 10;17:1881-1892. doi: 10.2147/NDT.S303292. 
      eCollection 2021.